Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lasofoxifene + Abemaciclib in ESR1-Mutated Breast Cancer
NCT04432454Phase 2Completed
- Sponsor
- Sermonix Pharmaceuticals
- Start
- Sep 2020
- Primary completion
- Jan 2025
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lasofoxifene in breast cancer, sponsored by Sermonix Pharmaceuticals. Primary endpoint: Safety and tolerability at 24 months. Started Sep 2020; status: completed.
02
Drugs
lasofoxifene
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04432454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04432454.